SYNAGEVA BIOPHARMA
Synageva is a biopharmaceutical company dedicated to developing and commercializing novel, next generation and follow on protein therapeutics that leverage the unique competitive advantages of their proprietary Synageva Expression Platform (SEPTM).
SYNAGEVA BIOPHARMA
Social Links:
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
1996-01-01
Address:
Waltham, Massachusetts, United States
Country:
United States
Website Url:
http://www.synageva.com
Total Employee:
251+
Status:
Active
Contact:
(781)357-9900
Email Addresses:
[email protected]
Total Funding:
597.4 M USD
Technology used in webpage:
Domain Not Resolving Person Schema Gravatar Profiles U.S. Server Location Visual Sciences
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
PharmAkea Therapeutics
PharmAkea is a biopharmaceutical company developing small molecule drug candidates targeting proteins in fibroproliferative diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2011-06-13 | Trimeris | Trimeris acquired by Synageva BioPharma | N/A |
Investors List
Covera Ventures
Covera Ventures investment in Venture Round - Synageva BioPharma
New Leaf Venture Partners
New Leaf Venture Partners investment in Venture Round - Synageva BioPharma
Baker Brothers Advisors LLC
Baker Brothers Advisors LLC investment in Venture Round - Synageva BioPharma
Yasuda Enterprise Development
Yasuda Enterprise Development investment in Venture Round - Synageva BioPharma
Baker Brothers Advisors LLC
Baker Brothers Advisors LLC investment in Series F - Synageva BioPharma
Yasuda Enterprise Development
Yasuda Enterprise Development investment in Series F - Synageva BioPharma
Covera Ventures
Covera Ventures investment in Series F - Synageva BioPharma
Tullis Health Investors
Tullis Health Investors investment in Series F - Synageva BioPharma
New Leaf Venture Partners
New Leaf Venture Partners investment in Series F - Synageva BioPharma
Tullis Health Investors
Tullis Health Investors investment in Series F - Synageva BioPharma
Official Site Inspections
http://www.synageva.com
- Host name: 172.67.179.137
- IP address: 172.67.179.137
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Synageva BioPharma"
Synageva BioPharma - Crunchbase Company Profile
Organization. Synageva BioPharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. …See details»
Synageva BioPharma Corp. - LinkedIn
Synageva BioPharma is a biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines for people living with rare diseases of high unmet medical need.See details»
Private Synageva's Business Overview - SEC.gov
Exhibit 99.1 . SYNAGEVA’S BUSINESS . Overview . Synageva BioPharma Corp. (“Synageva”) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for …See details»
Organization | Synageva Biopharma
Synageva Biopharma Report issue. For profit Phase 2 Phase 4. Founded: Athens GA United States ... Organization Overview. First Clinical Trial. 2007 NCT00497809. First Marketed Drug. …See details»
Synageva BioPharma - Funding, Financials, Valuation & Investors
Synageva BioPharma is registered under the ticker NASDAQ:GEVA . Synageva BioPharma is funded by 9 investors. Covera Ventures and New Leaf Venture Partners are the most recent …See details»
Synageva BioPharma - Products, Competitors, Financials, …
Prior to that, from September 2014 to June 2015, Mr. Bazemore served as the Chief Operating Officer of Synageva BioPharma Corp., where he established the company’s global commercial …See details»
Synageva - Wikiwand
Synageva BioPharma Corp. was a publicly listed biopharmaceutical company headquartered in Lexington, Massachusetts dedicated to discovering, developing and delivering medicines for …See details»
Alexion to bolster rare disease offering with $8.4 billion deal - Yahoo
May 6, 2015 Alexion Pharmaceuticals Inc on Wednesday said it agreed to buy Synageva BioPharma Corp for $8.4 billion, more than twice its market value, to expand its offering of …See details»
Alexion Pharma to pay $8.4 billion for Synageva BioPharma
May 6, 2015 Alexion Pharmaceuticals will pay a huge premium to buy Synageva BioPharma in an $8.4-billion deal for a rare disease treatment maker that lost nearly $60 million in the first …See details»
Synageva BioPharma - Overview, News & Similar companies
Synageva is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The company's …See details»
Synageva BioPharma Company Profile | Management and
Synageva BioPharma Profile and History Synageva is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with …See details»
Alexion to acquire Synageva for $8.4 billion
May 7, 2015 Synageva is focused on therapeutic products for patients with rare diseases “Synageva is an ideal strategic and operational fit for Alexion that aligns with what we know …See details»
Synageva BioPharma Company Profile 2024: Valuation, Investors ...
Publication ID Patent Title Status First Filing Date Technology (CPC) Citations; EP-2820032-A1: Truncated lysosomal acid lipase: Inactive: 02-Mar-2012: EP-2820032-A4See details»
Synageva BioPharma Corporation - The New York Times
Alexion to Buy Synageva BioPharma in $8.4 Billion Deal. The deal taps into the interest for so-called orphan drugs, where companies can charge hundreds of thousands of dollars a year to …See details»
Synageva BioPharma - Contacts, Employees, Board Members
Organization. Synageva BioPharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. ... Synageva BioPharma has 1 …See details»
Synageva BioPharma: A Pipeline of Therapeutic Programs - Yahoo …
May 13, 2015 Synageva also has an active investigational new drug application with the U.S. Food and Drug Administration to evaluate its second program, SBC-103, a first-mover enzyme …See details»
Companies To Watch: Synageva BioPharma - Life Science Leader
Oct 1, 2012 Synageva has not signaled a price for SBC-102 if approved, but the company’s presentation to analysts cites Cerezyme and other high-ticket orphans to indicate potential …See details»
Synageva BioPharma and Trimeris Announce Merger Agreement
Jun 13, 2011 Synageva BioPharma Corp. is dedicated to discovering, developing and delivering medicines for patients with rare diseases and unmet medical need. The Company has …See details»
EX-99.3 - SEC.gov
Exhibit 99.3 . SYNAGEVA BIOPHARMA ANNOUNCES NEW PIPELINE PROGRAMS AND OTHER COMPANY PROGRESS . LEXINGTON, Mass., January 5, 2015 — Synageva …See details»